June 21, 2017Fort Lauderdale, Fla. and WASHINGTON and PARIS |
Vigilant Biosciences Announces Further Clinical Data in Support of its OncAlert® Oral Cancer Product Line at IFOS ENT World Congress 2017 Symposium and at Annual MASCC MeetingCompany to exhibit as Bronze Sponsor of IFOS ENT World Congress and present interim analysis of European clinical studies in support of its OncAlert Oral Cancer product line Vigilant Biosciences,… Read |
×
June 13, 2017Fort Lauderdale, FLA. |
Vigilant Biosciences Announces Grant Award from National Institutes of HealthVigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the that it has received an award as… Read |
May 10, 2017 |
Vigilant Biosciences Announces Commencement of FDA Studies for OncAlert® Cancer TestCompany begins drive toward FDA clearance of first and only test to detect a tumor-initiating stem cell-associated biomarker for oral and oropharyngeal cancer Vigilant Biosciences, Inc., a leading innovator and… Read |
March 30, 2017Fort Lauderdale, Fla. |
Oral Cancer Awareness Survey Reveals 81 Percent of U.S. Adults Want to Be Screened for Oral Cancer During Routine Dental Check-ups; Only 29 Percent Actually AreSurvey conducted by Vigilant Biosciences, Head and Neck Cancer Alliance, Oral Cancer Foundation and Support for People with Oral and Head and Neck Cancer reveals low awareness, misconceptions and desire… Read |
March 22, 2017Fort Lauderdale, Fla. |
Vigilant Biosciences Announces Multiple Poster Presentations in Support of OncAlert® Oral Cancer and OncAlert Labs Product LinesVigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the acceptance of five abstracts regarding data related… Read |